||EPS - Basic
||Market Cap (m)
Amarin Share Discussion Threads
Showing 201 to 220 of 225 messages
(But is it a Buy now?)|
|Place your bets for tomorrows decision.|
|Nice move up.
|Upward trend firmly established now imo.|
|Part of Jim Mellon's article on t1ps.com today...
"...Summit plc*, the DMD drug development company of which I am a director, did a useful placing since when the shares have risen over 55%.
Plethora has moved up significantly, indeed, nearly 5x this year, and again I remain a large shareholder and director. Other stocks I am keen on, (caveat emptor) is Amarin in the US which I think is a prime takeover candidate, and Repros. Both are US pharma companies in the early stages of product commercialization and both are cheap according to our analysis."|
"jim mellon (@jimmhk)
next week I am looking to remain short government bonds in all markets, looking for gold at 1335, and watching Amarin closely as T/O close"|
|Once we get above 6 we'll be off to the races imo.
Best stock up beforehand.|
|Leerink maintains Outperform on Amarin
* Leerink Swann maintains its Outperform rating on shares of Amarin (AMRN) following the company's Q2 report.
* Analyst Joseph Schwartz expects "approval of Vascepa for mixed-dyslipidemia" come December 20 (the PDUFA date).
* Price target is nonetheless adjusted down to $18 from $20.
|Mellon Man still a big fan here...
"jim mellon @jimmhk 23h
trova has moved up a lot..target 10-12.faves now synergy, amarin and arrowhead.Arrohead target 10.rna is getting big again..short aud"|
|Into August now. So that all important December date is getting ever closer.|
|Worth remembering that NASDAQ stocks bought in the UK have full ISA elligibility.|
|Tweet from Jim Mellon
"just off the phone with CEO Amarin Corp..230 min cash, scripts rising, new indication likely approved for Vascepa year end.love the stock!"|
|"3 Biotech Stocks That Could Double by Next Summer
1. Amarin (NASDAQ: AMRN )
Amarin's stock has dropped like a sinking fastball over the past year. Shares are down more than 60% since last summer and around 30% year-to-date. The steep decline stems largely from Amarin tackling commercialization of Vascepa on its own. At least at first glance, the odds that shares could double by next summer seem slim at best.
What looking at the stock's chart doesn't reveal, though, is that Amarin expects a huge decision by the Food and Drug Administration by Dec. 20. The FDA will determine whether the company's highly concentrated fish oil drug Vascepa can be marketed for treating patients with high triglyceride levels between 200 mg/dL and 499 mg/dL.
Amarin already won regulatory approval for selling Vascepa for super-high triglyceride levels of 500 mg/dL and above. However, the potential market size that would open up if the FDA grants approval in December is 10 times the size of the company's market available currently. The average analysts' price target for Amarin, according to Thomson/First Call, is $16.50 -- more than triple the stock's price now."
Company website: http://www.amarincorp.com/|
Last month, according to Sonderby, Amarin issued a filing that Elan had paid it $700,000 to regain control of a product that the latter had out-licensed for free.
However, "[t]hese events would simply reflect a series of poor decisions by Elan's management were it not for Amarin's insistence, in their recent disclosure, on highlighting that Elan's Chief Financial Officer, Shane Cooke, is the brother of Amarin's then Chief Operating Officer, Alan Cooke," he adds. He goes on to write that U.S. companies are required to report insider dealings and conflicts of interest at an officer or director level, especially where family members are involved. He then questions Elan's claims that it practices a high level of corporate governance and asks the company's board to help him understand the transaction
Read more: Sonderby strikes chord with angry Elan investors - FiercePharma http://www.fiercepharma.com/story/sonderby-strikes-chord-angry-elan-investors/2010-08-19#ixzz0xYHeNiPG
Closing Price: $1.64|
DRUG DEVELOPMENT group Amarin has three weeks to source long-term funding to secure its future.|
|Drug development company Amarin agrees bridging finance
Drug development company Amarin has agreed bridging finance to fund company operations for the rest of 2009.
Chief executive Tom Lynch said current investors in the group and some of its directors had agreed to fund the $2.6 million (1.8 million) package.
He said the Nasdaq-listed business would continue "ongoing discussions" with both existing and potential investors in an effort to secure longer term funding.
Mr Lynch said he was "very grateful for the support of a number of long-standing investors in this bridge financing".
The bridging finance consists of convertible loan notes and warrants. The notes will pay interest of 8 per cent per annum. The warrants entitle investors to buy shares up to half their loan note entitlement. The bridging finance became necessary when investors who put up $28 million in May 2008 indicated they would not exercise their option to invest a further $28 million.|